Novel agents in development for the treatment of depression

CNS Spectrums

Volumn 18, Issue SUPPL.1, 2013, Pages 37-41

  Grady, Meghan M ^a   Stahl, Stephen M ^a,b,c,d  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CA State Dept of Health Services   (United States)

Author keywords

Antidepressant; glutamate; multimodal; novel; triple reuptake

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; AMITIFADINE; ANTIDEPRESSANT AGENT; AZD 6765; CIMICOXIB; CURCUMIN; DEXTROMETHORPHAN; EDIVOXETINE; INFLIXIMAB; KETAMINE; LAMOTRIGINE; LIAFENSINE; MEMANTINE; METYRAPONE; MIFEPRISTONE; MILNACIPRAN; MK 0657; NELIVAPTAN; PEXACERFONT; RADIPRODIL; RILUZOLE; TEDATIOXETINE; TRAXOPRODIL; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORTIOXETINE;

BRAIN SIZE; CLINICAL EFFECTIVENESS; DEPRESSION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GLUTAMATERGIC NEUROTRANSMISSION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING; UPREGULATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID AGENTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROTRANSMITTER UPTAKE INHIBITORS; PITUITARY-ADRENAL SYSTEM;

EID: 84890801302     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000758     Document Type: Review

References (28)

1. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.
2. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004; 56(3): 140-145.
3. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995; 15(11): 7539-7547.
4. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20(24): 9104-9110.
5. Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep. 2012; 14(6): 643-649.
6. Li N, Lee B, Liu RJ, et al. mTOr-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994): 959-964.
7. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011; 69(8): 754-761.
8. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012; 338(6103): 68-72.
9. Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets. 2009; 10(11): 1069-1084.
10. Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs. 2011; 20(8): 1107-1130.
11. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 2012; 17(1): 105-126.
12. Bang-Anderson B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206-3221.
13. Westrich I, Pehrson A, Zhong H, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012; 5(suppl 1): 47.
14. Mork A, Montezinho LP, Miller S, et al. Vortioxetine (LU AA21004), a novel multimodal antidepressant, enhanced memory in rats. Pharmacol Biochem Behav. 2013; 105: 41-50.
15. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4): 351-354.
16. Zarate CA Jr, Singh JB, Carlson PH, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856-864.
17. Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013; 18(4): 171-174.
18. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012; 35(1): 47-56.
19. Stahl SM. Mechanism of action of dextromethorphan/quinidine. CNS Spectr. In press.
20. Liu RJ, Aghajanian GK. Stress blunts serotonin-and hypocretinevoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci USA. 2008; 105(1): 359-364.
21. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission. Science. 2012; 338(6103): 72-75.
22. Liu RJ, Lee FS, Li XY, et al. Brain-derived neurotrophic factor Val66Met al.lele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012; 71(11): 996-1005.
23. McClelland S, Korosi A, Cope J, et al. Emerging roles of epigenetic mechanisms in the enduring effects of early-life stress and experience on learning and memory. Neurobiol Learn Mem. 2011; 96(1): 79-88.
24. Brunson KL, Kramar E, Lin B, et al. Mechanisms of late-onset cognitive decline after early-life stress. J Neurosci. 2005; 25(41): 9328-9338.
25. Ivy AS, Rex CS, Chen Y, et al. Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors. J Neurosci. 2010; 30(39): 13005-13015.
26. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006; 59(12): 1116-1127.
27. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004; 161(11): 1957-1966.
28. Dwivedi Y, Rizavi HS, Connley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003; 60(8): 804-815.